Completed PHASE1 INTERVENTIONAL NCT00001302

A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833

Sponsor: National Cancer Institute (NCI)

Conditions Breast Cancer Kidney Neoplasm Lymphoma Neoplasm Metastasis Ovarian Cancer

Interventions PSC 833

Updated 5 times since 2017 Last updated: Mar 3, 2008 Started: Sep 30, 1992 Completion: Jun 30, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Breast Cancer and Kidney Neoplasm and is currently completed. National Cancer Institute (NCI) leads this study, which shows 5 recorded versions since 1992 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Sep 1992

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States